UCLA's Dr. Antoni Ribas Discusses PD1 and PD-L1 Targeted Cancer Drugs

3 years ago
Team Xplore's picture

Antoni Ribas, M.D. of the UCLA Jonsson Comprehensive Cancer Center is involved in trials testing new cancer drugs targeting the cell surface molecule called PD-L1, and the immune cell receptors PD1. Early data from these trails involving non-small cell lung cancer, renal cancer and melanoma have demonstrated impressive results that can lead to new treatments for the disease. In the video interview, Dr. Ribas explains the trial test data published so far, and previews new data to be seen at the upcoming American Society of Clinical Oncology (ASCO) meeting.